Raymond James Financial
GALT icon

Raymond James Financial’s Galectin Therapeutics GALT Stock Holding History

Raymond James Financial’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66K Sell
14,217
-750
-5% -$1.94K ﹤0.01% 5226
2026
Q1 		$41.8K Buy
14,967
+1,250
+9% +$3.8K ﹤0.01% 5140
2025
Q4 		$57.1K Buy
+13,717
New +$72.2K ﹤0.01% 4998
2025
Q3 		– Sell
-10,550
Closed -$22.3K – 5636
2025
Q2 		$22.3K Sell
10,550
-1,000
-9% -$1.5K ﹤0.01% 5554
2025
Q1 		$14.1K Hold
11,550
– – ﹤0.01% 4752
2024
Q4 		$14.9K Buy
+11,550
New +$27.7K ﹤0.01% 4751

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Raymond James Financial's GALT Position: Q2 2026 in Review

Raymond James Financial reduced its Galectin Therapeutics (GALT) stake by 5% in Q2 2026, selling an estimated $1.94K and leaving 14,217 shares worth $66K. The position accounts for ﹤0.01% of the portfolio, ranked #5226.

Raymond James Financial first reported a position in GALT in Q4 2024 and has held it in 6 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Raymond James Financial held 14,217 shares of Galectin Therapeutics worth $66K as of Q2 2026.
  • Raymond James Financial sold 750 Galectin Therapeutics shares in Q2 2026, an estimated $1.94K.
  • Galectin Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5226 holding.
  • Raymond James Financial first reported a position in Galectin Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.